Clinical trial · Interventional
The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon
NCT00176618CI-TRIAL-00002877terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): principal Investigator left institution
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness of curcumin in reducing the number of aberrant crypt foci (ACF) in the colon.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aberrant Crypt Foci | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| curcumin | Drug | — | UNRESOLVED |
| sulindac | Drug | Sulindac | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the effects of curcumin or the NSAID sulindac on the number of ACF in the left colon and rectum of normal volunteers found to have them on an initial magnifying chromoendoscopic screening exam
- timeFrame
- 48 months
Secondary outcomes (1)
- measure
- To determine the turnover (proliferation, apoptosis, and differentiation) of colorectal epithelial cells in the crypts in situ in response to each treatment
- timeFrame
- 48 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects must be eligible for colorectal cancer (CRC) screening/surveillance by current criteria. * Subjects must have at least 5 ACF on eligibility chromosigmoidoscopy examination. Exclusion Criteria: Subjects must not have: * Alcohol consumption of greater than 2 glasses of wine or beer per day or illicit recreational drug use * Platelet or coagulation abnormalities, or personal history of a bleeding disorder, including individuals taking warfarin. * High risk for developing endocarditis (history of endocarditis or rheumatic fever, cardiac valve prostheses, or mitral valve prolapse that requires antibiotic prophylaxis). * Uncontrolled hypertension, diabetes, or chronic congestive heart failure. * Renal insufficiency defined as a serum creatinine \> 2.5 mg/dl * History of colorectal surgery with removal of the distal 60 cm of colon or rectum. * History of other gastrointestinal mucosal epithelial diseases (such as Barrett's esophagus, chronic or recurrent peptic ulcer disease, celiac sprue or other disorders of nutrient absorption).
References
Publications (0)
Data not yet available
No reference posted for this study.